The impact of N-nitrosamine impurities on clinical drug development
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The impact of N-nitrosamine impurities on clinical drug development
Authors
Keywords
-
Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-01-25
DOI
10.1016/j.xphs.2023.01.017
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N-Nitrosamine Impurities
- (2022) Krista L. Dobo et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Rifampin drug‐drug‐interaction studies; reflections on the nitrosamine impurities issue
- (2022) Aernout van Haarst et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A literature review of liver function test elevations in rifampin drug–drug interaction studies
- (2022) Sherry M. Ibrahim et al. CTS-Clinical and Translational Science
- Metabolic Activation and DNA Interactions of Carcinogenic N-Nitrosamines to Which Humans Are Commonly Exposed
- (2022) Yupeng Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies
- (2022) Jayaprakasam Bolleddula et al. CTS-Clinical and Translational Science
- PBPK perspective on alternative CYP3A4 inducers for rifampin
- (2022) Kuan‐Fu Chen et al. CPT-Pharmacometrics & Systems Pharmacology
- The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals
- (2022) Joerg Schlingemann et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Permitted daily exposure limits for noteworthy N‐nitrosamines
- (2021) George E. Johnson et al. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
- The nitrosamine contamination of drugs, part 3: Quantification of 4-Methyl-1-nitrosopiperazine in rifampicin capsules by LC-MS/HRMS
- (2021) Jonas Wohlfart et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- A genome-wide portrait of pervasive drug contaminants
- (2021) Joseph Uche Ogbede et al. Scientific Reports
- Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications
- (2021) Kate Li et al. International Journal of Environmental Research and Public Health
- Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data
- (2020) Andrew Thresher et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Critical review of major sources of human exposure to N -nitrosamines
- (2018) Adam J. Gushgari et al. CHEMOSPHERE
- Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study
- (2018) Anton Pottegård et al. BMJ-British Medical Journal
- Dietary exposure to volatile and non-volatile N-nitrosamines from processed meat products in Denmark
- (2015) S.S. Herrmann et al. FOOD AND CHEMICAL TOXICOLOGY
- Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers
- (2012) S Oswald et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics
- (2012) E D Kharasch et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Enzyme induction with antiepileptic drugs: Cause for concern?
- (2012) Martin J. Brodie et al. EPILEPSIA
- Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers
- (2010) L. Vlase et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Carbamazepine,HLA-B*1502and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations
- (2008) P Brent Ferrell et al. PHARMACOGENOMICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started